Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Eur J Pharm Sci. 2019 Mar 28;133:86–94. doi: 10.1016/j.ejps.2019.03.020

Table 1.

EC50 of NMS-873 against influenza A or B viruses.

Influenza Strains Drug sensitivity EC50(nM)a SIb
A/Washington/29/2009 (H1N1) Amantadine Resistant
Oseltamivir Resistant		 41 ± 5 66
A/North Carolina/39/2009 (H1N1) 35 ± 5 78
A/Texas/04/2009 (H1N1) 38 ± 5 71
A/Denmark/528/2009 (H1N1) 39 ± 4 70
A/WSN/1933 (H1N1) Amantadine Resistant
Oseltamivir Sensitive		 37 ± 2 74
A/California/07/2009 (H1N1) 56 ± 5 49
A/Switzerland/9715293/2013 (H3N2) 21 ± 2 129
B/Wisconsin/1/2010 (Yamagata) Amantadine Resistant
Oseltamivir Sensitive		 35 ± 5 78
B/Bris/60/2008 (Victoria) 28 ± 8 97
a

, EC50 was determined in the plaque assay using the ST6Gal I–overexpressing MDCK cells (AX-4). Plaque areas were quantified for calculation of EC50 using Image J and Prism 5;

b

, SI is selectivity index, which was calculated by CC50/EC50.